Double amplifications of CDK4 and MDM2 in a gastric inflammatory myofibroblastic tumor mimicking cancer with local invasion of the spleen and diaphragm

ABSTRACT Inflammatory myofibroblastic tumor (IMT) is currently recognized as an intermediate mesenchymal neoplasm. It can arise anywhere in the body, but it is particularly common in the lungs. Gastric IMT is very rare in adults. In this study, we report a case of a 68-year-old woman with IMT in the gastric cardia, with invasion into the spleen and diaphragm. Because of its location and aggressive clinical features, it was first mistaken for gastric cancer. However, pathology and immunohistochemistry were used to finally confirm the diagnosis of IMT after total resection of the tumor and spleen and partial resection of the diaphragm. In order to provide better understanding of this rare tumor, targeted next-generation sequencing (NGS) and IHC were performed to assess genetic and protein abnormalities of the tumor. Both IHC and NGS were found to be negative for ALK or other gene fusions. However, double amplification of CDK4 and MDM2 were found by NGS, and IHC also found CDK4 and MDM2 to be positive. To the best of our knowledge, this is the first gastric IMT report to show double invasion of the spleen and the diaphragm, and double amplification of CDK4 and MDM2 in IMT are also reported for the first time. This genomic aberration with protein overexpression is the most likely tumorigenic driver of this rare and aggressive tumor.

[1]  S. Kittur,et al.  Inflammatory Myofibroblastic Tumor of the Stomach Presenting as an Exophytic Mass - A Diagnostic Dilemma. , 2017, Turk patoloji dergisi.

[2]  Yuehua Wu,et al.  High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases. , 2017, Cancer genetics.

[3]  A. Italiano,et al.  Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas , 2017, Journal of Hematology & Oncology.

[4]  Mutian Zhang,et al.  Anaplastic lymphoma kinase: Role in cancer and therapy perspective , 2015, Cancer biology & therapy.

[5]  Agnieszka K. Witkiewicz,et al.  The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.

[6]  P. Cin,et al.  Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors , 2015, Modern Pathology.

[7]  Fan Zhou,et al.  A large inflammatory myofibroblastic tumor involving both stomach and spleen: A case report and review of the literature , 2014, Oncology letters.

[8]  P. Stephens,et al.  Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. , 2014, Cancer discovery.

[9]  Hui-fang Wang,et al.  High fever as an initial symptom of primary gastric inflammatory myofibroblastic tumor in an adult woman. , 2014, International journal of clinical and experimental medicine.

[10]  C. Fletcher,et al.  WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition , 2014, Pathology.

[11]  F. Marincola,et al.  Characterization of human melanoma cell lines and melanocytes by proteome analysis , 2011, Cell cycle.

[12]  A. Dicker,et al.  The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. , 2011, Cell cycle.

[13]  Lixin Wei,et al.  Primary gastric inflammatory myofibroblastic tumor: a clinicopathologic and immunohistochemical study of 5 cases. , 2010, Pathology, research and practice.

[14]  Y. Albayrak,et al.  Inflammatory Myofibroblastic Tumor of the Stomach in an Adult Woman: A Rare Intermittent Cause of Gastric Outlet Obstruction , 2010, Tumori.

[15]  C. Fletcher,et al.  Inflammatory Myofibroblastic Tumor: Comparison of Clinicopathologic, Histologic, and Immunohistochemical Features Including ALK Expression in Atypical and Aggressive Cases , 2007, The American journal of surgical pathology.

[16]  E. Gilbert-Barness,et al.  INFLAMMATORY MYOFIBROBLASTIC TUMOR OF THE MIDESOPHAGUS , 2007, Fetal and pediatric pathology.

[17]  N. Nikitakis,et al.  Oral inflammatory myofibroblastic tumor demonstrating ALK, p53, MDM2, CDK4, pRb, and Ki-67 immunoreactivity in an elderly patient. , 2005, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[18]  D. Schrump,et al.  Identification of CARS-ALK Fusion in Primary and Metastatic Lesions of an Inflammatory Myofibroblastic Tumor , 2003, Laboratory Investigation.

[19]  I. Cha,et al.  Inflammatory myofibroblastic tumor of the stomach with peritoneal dissemination in a young adult: imaging findings in a case report , 2003, Abdominal Imaging.

[20]  N. Nikitakis,et al.  MDM2 and CDK4 expression in carcinosarcoma of the esophagus: comparison with squamous cell carcinoma and review of the literature. , 2002, Experimental and molecular pathology.

[21]  M. Oren,et al.  Regulation of p53 , 2002, Annals of the New York Academy of Sciences.

[22]  L. Sobin,et al.  Inflammatory myofibroblastic tumors (inflammatory pseudotumors) of the gastrointestinal tract: how closely are they related to inflammatory fibroid polyps? , 2002, Human pathology.

[23]  L. Sobin,et al.  Immunohistochemical Spectrum of GISTs at Different Sites and Their Differential Diagnosis with a Reference to CD117 (KIT) , 2000, Modern Pathology.

[24]  Margaret Ashcroft,et al.  Regulation of p53 stability , 1999, Oncogene.

[25]  C. Coffin,et al.  Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey. , 1998, Seminars in diagnostic pathology.

[26]  G. Lozano,et al.  Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. , 1997, Genes & development.

[27]  C. Jm.  [Histologic classification of soft tissue tumors (WHO, 1994)]. , 1994 .

[28]  J. Coindre.  [Histologic classification of soft tissue tumors (WHO, 1994)]. , 1994, Annales de pathologie.